CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cardax Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cardax Inc
SUITE 129, 2800 WOODLAWN DRIVE
Phone: (808) 457-1400p:808 457-1400 HONOLULU, HI  96822  United States Ticker: CDXICDXI
Business Summary
Cardax, Inc. is a geroscience company focused on pharmaceutical and nutraceutical applications of astaxanthin. The Company markets ZanthoSyn, an astaxanthin dietary supplement for lifespan and health span (inflammatory health), including joint and muscle function, cognitive performance, and cardiovascular health. ZanthoSyn is available through its commercial Website. ZanthoSyn contains pure astaxanthin prepared by natural product total synthesis. The Company is also advancing CDX-101, its pharmaceutical candidate, for the diseases of aging. CDX-101 is an astaxanthin Rx candidate for cardiovascular inflammation and dyslipidemia. CDX-301 is its zeaxanthin pharmaceutical candidate for macular degeneration. It may seek to monetize its CDX-301 pharmaceutical assets through licensing or sale.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202112/31/2020YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer David G.Watumull 71 8/31/2021 2/7/2014
Chief Financial Officer, Chief Operating Officer, Assistant Treasurer, Company Secretary David M.Watumull 39 8/31/2021 2/7/2014

Business Names
Business Name
CDXI
CDXID

General Information
Number of Employees: 10 (As of 12/31/2020)
Outstanding Shares: 802,516 (As of 5/14/2021)
Shareholders: 456
Stock Exchange: OTC
Federal Tax Id: 454484428
Fax Number: (808) 237-5901


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 6, 2025